Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net cash flows from operating activities:
Net (loss) income	$ (14,834)	$ (16,682)	$ 1,720
Adjustments to reconcile net (loss) income to net cash from operating activities:
Depreciation and amortization	23,977	20,712	18,317
Non-cash compensation	10,711	6,912	8,799
Change in fair value of contingent consideration	8,870	4,523
Non-cash lease expense	7,521	7,145	5,009
Write-down of inventories and deferred preservation costs	5,377	3,443	1,488
Write-off of Endospan Option	4,944
Non-cash interest expense	2,005	3,656	1,631
Change in fair value of long-term loan receivable	409	4,949
Deferred income taxes	(4,470)	4,283	(2,305)
Gain from sale of non-financial assets	(15,923)
Other	2,060	124	551
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(1,404)	(2,720)	(6,177)
Accounts payable, accrued expenses, and other liabilities	(1,893)	(9,157)	251
Receivables	(11,560)	9,938	(5,332)
Inventories and deferred preservation costs	(18,375)	(24,757)	(8,125)
Net cash flows (used in) provided by operating activities	(2,585)	12,369	15,827
Net cash flows from investing activities:
Proceeds from sale of non-financial assets, net	19,000
Ascyrus Acquisition, net of cash acquired		(59,119)
Payments for Endospan Agreements		(5,000)	(15,000)
Capital expenditures	(13,091)	(7,328)	(8,072)
Other	(249)	(1,681)	(871)
Net cash flows provided by (used in) investing activities	5,660	(73,128)	(23,943)
Net cash flows from financing activities:
Proceeds from exercise of stock options and issuance of common stock	3,756	2,432	4,758
Proceeds from issuance of convertible debt		100,000
Proceeds from revolving line of credit		30,000
Proceeds from financing insurance premiums		2,815
Repayment of revolving line of credit		(30,000)
Redemption and repurchase of stock to cover tax withholdings	(1,914)	(1,995)	(2,743)
Payment of debt issuance costs	(2,219)	(3,647)
Repayment of debt	(3,085)	(5,346)	(2,780)
Payment of contingent consideration	(8,200)
Other	(561)	(651)	(728)
Net cash flows (used in) provided by financing activities	(12,223)	93,608	(1,493)
Effect of exchange rate changes on cash, cash equivalents, and restricted securities	2,200	(5,185)	1,667
(Decrease) increase in cash, cash equivalents, and restricted securities	(6,948)	27,664	(7,942)
Cash, cash equivalents, and restricted securities, beginning of year	61,958	34,294	42,236
Cash, cash equivalents, and restricted securities, end of year	$ 55,010	$ 61,958	$ 34,294